4.8644
price up icon6.16%   0.1544
 
loading
Schlusskurs vom Vortag:
$4.71
Offen:
$4.71
24-Stunden-Volumen:
9,723
Relative Volume:
0.34
Marktkapitalisierung:
$25.19M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.35M
KGV:
-2.0439
EPS:
-2.38
Netto-Cashflow:
$-11.88M
1W Leistung:
-4.03%
1M Leistung:
-10.07%
6M Leistung:
-23.90%
1J Leistung:
+99.20%
1-Tages-Spanne:
Value
$4.7087
$5.00
1-Wochen-Bereich:
Value
$4.63
$5.227
52-Wochen-Spanne:
Value
$2.38
$11.79

Lipocine Inc Stock (LPCN) Company Profile

Name
Firmenname
Lipocine Inc
Name
Telefon
801 994 7383
Name
Adresse
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Name
Mitarbeiter
17
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
LPCN's Discussions on Twitter

Vergleichen Sie LPCN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
LPCN 4.91 25.19M 0 -16.35M -11.88M -2.38
VRTX 449.07 115.43B 10.63B -479.80M -1.35B 13.33
REGN 748.73 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 587.28 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 247.66 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 106.61 24.89B 3.30B -501.07M 1.03B 11.54

Lipocine Inc Stock (LPCN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-06-24 Eingeleitet Cantor Fitzgerald Overweight
2020-12-10 Hochstufung Ladenburg Thalmann Neutral → Buy
2018-01-12 Bestätigt H.C. Wainwright Buy
2018-01-11 Herabstufung Canaccord Genuity Buy → Hold
2017-12-08 Fortgesetzt H.C. Wainwright Buy
2016-10-07 Eingeleitet H.C. Wainwright Buy
2015-07-22 Eingeleitet ROTH Capital Buy
2015-06-23 Eingeleitet Canaccord Genuity Buy
Alle ansehen

Lipocine Inc Aktie (LPCN) Neueste Nachrichten

pulisher
Nov 18, 2024

Lipocine's LPCN 1148 Shows Breakthrough Results in Liver Disease Clinical Trial | LPCN Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 09, 2024

Lipocine (NASDAQ:LPCN) Announces Financial Results for the Quarter Ended September 30, 2024 - Defense World

Nov 09, 2024
pulisher
Nov 08, 2024

When the Price of (LPCN) Talks, People Listen - Stock Traders Daily

Nov 08, 2024
pulisher
Nov 07, 2024

Lipocine: Q3 Earnings Snapshot - CT Insider

Nov 07, 2024
pulisher
Nov 07, 2024

Lipocine Inc. (LPCN) Quarterly 10-Q Report - Quartz

Nov 07, 2024
pulisher
Nov 07, 2024

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024 - PR Newswire

Nov 07, 2024
pulisher
Nov 07, 2024

Lipocine Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024
pulisher
Nov 06, 2024

Lipocine (NASDAQ:LPCN) Presents Positive Data on LPCN 2401 at Obesity Society Conference - Defense World

Nov 06, 2024
pulisher
Nov 04, 2024

Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference - GuruFocus.com

Nov 04, 2024
pulisher
Oct 31, 2024

Lipocine inks deal to bring TLANDO to South Korea - Investing.com

Oct 31, 2024
pulisher
Oct 31, 2024

Lipocine Partners With SPC Korea For TLANDO In South Korea - Contract Pharma

Oct 31, 2024
pulisher
Oct 31, 2024

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea - Morningstar

Oct 31, 2024
pulisher
Oct 30, 2024

Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study i - GuruFocus.com

Oct 30, 2024
pulisher
Oct 28, 2024

Trading (LPCN) With Integrated Risk Controls - Stock Traders Daily

Oct 28, 2024
pulisher
Oct 28, 2024

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1 - GuruFocus.com

Oct 28, 2024
pulisher
Oct 25, 2024

Lipocine Announces Completion of Dosing in Pivotal Study of Post - GuruFocus.com

Oct 25, 2024
pulisher
Oct 18, 2024

(LPCN) Trading Signals - Stock Traders Daily

Oct 18, 2024
pulisher
Oct 16, 2024

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Bod - GuruFocus.com

Oct 16, 2024
pulisher
Oct 11, 2024

Lipocine reports promising oral brexanolone study results By Investing.com - Investing.com Australia

Oct 11, 2024
pulisher
Oct 11, 2024

Lipocine reports promising oral brexanolone study results - Investing.com India

Oct 11, 2024
pulisher
Oct 10, 2024

Lipocine Enters Exclusive Supply And Distribution Agreement With Pharmalink - Contract Pharma

Oct 10, 2024
pulisher
Oct 10, 2024

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results - PR Newswire

Oct 10, 2024
pulisher
Oct 09, 2024

Lipocine signs supply and distribution agreement with Pharmalink for Tlando - Yahoo Finance

Oct 09, 2024
pulisher
Oct 08, 2024

Lipocine partners with Pharmalink for GCC distribution of TLANDO - Investing.com

Oct 08, 2024
pulisher
Oct 08, 2024

Lipocine partners with Pharmalink for GCC distribution of TLANDO By Investing.com - Investing.com Nigeria

Oct 08, 2024
pulisher
Oct 08, 2024

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries - PR Newswire

Oct 08, 2024
pulisher
Oct 02, 2024

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024 - Citizentribune

Oct 02, 2024
pulisher
Sep 24, 2024

Alliance Global Partners Initiates Coverage on Lipocine (NASDAQ:LPCN) - Defense World

Sep 24, 2024
pulisher
Sep 21, 2024

Lipocine (NASDAQ:LPCN) Upgraded to Buy at StockNews.com - Defense World

Sep 21, 2024
pulisher
Sep 18, 2024

‘Lubber Pandhu also has strong emotions beyond cricket’ - DTNEXT

Sep 18, 2024
pulisher
Sep 18, 2024

Louisiana-Pacific director sells $245,750 in company stock By Investing.com - Investing.com Canada

Sep 18, 2024
pulisher
Sep 18, 2024

PLRX’s 52-Week Rollercoaster: From $10.29 to $19.62 – What’s Next for Investors? - The InvestChronicle

Sep 18, 2024
pulisher
Sep 17, 2024

Health Check: Paradigm receives FDA guidance on proposed trial for dodgy knees - Stockhead

Sep 17, 2024
pulisher
Sep 17, 2024

Pliant Therapeutics (NASDAQ:PLRX) Sees Large Volume Increase - MarketBeat

Sep 17, 2024
pulisher
Sep 17, 2024

Liquidia Corp [LQDA] Investment Guide: What You Need to Know - Knox Daily

Sep 17, 2024
pulisher
Sep 17, 2024

MediPharm Labs Corp. - Baystreet.ca

Sep 17, 2024
pulisher
Sep 17, 2024

A stock that deserves closer examination: Lipella Pharmaceuticals Inc (LIPO) - US Post News

Sep 17, 2024
pulisher
Sep 16, 2024

PLRX’s latest rating updates from top analysts. - Knox Daily

Sep 16, 2024
pulisher
Sep 16, 2024

Labcorp Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch

Sep 16, 2024
pulisher
Sep 16, 2024

Pliant Therapeutics (NASDAQ:PLRX) Shares Gap Up to $12.00 - MarketBeat

Sep 16, 2024
pulisher
Sep 14, 2024

Prudential PLC Sells 7,956 Shares of Laboratory Co. of America Holdings (NYSE:LH) - MarketBeat

Sep 14, 2024
pulisher
Sep 14, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Sep 14, 2024
pulisher
Sep 12, 2024

Research Analysts Set Expectations for Pliant Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:PLRX) - Defense World

Sep 12, 2024
pulisher
Sep 05, 2024

Lipocine Inc. filed SEC Form 8-K: Financial Statements and Exhibits - Quantisnow

Sep 05, 2024
pulisher
Sep 05, 2024

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek® - Kilgore News Herald

Sep 05, 2024
pulisher
Aug 30, 2024

Lipocine (NASDAQ:LPCN) Downgraded by StockNews.com to “Hold” - Defense World

Aug 30, 2024
pulisher
Aug 27, 2024

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference – Company Announcement - Financial Times

Aug 27, 2024
pulisher
Aug 27, 2024

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference - StockTitan

Aug 27, 2024
pulisher
Aug 22, 2024

Sarcopenia Market to Grow Positively at a Paltry CAGR During - openPR

Aug 22, 2024
pulisher
Aug 17, 2024

StockNews.com Lowers Lipocine (NASDAQ:LPCN) to Hold - Defense World

Aug 17, 2024
pulisher
Aug 12, 2024

Lipocine (NASDAQ:LPCN) Raised to Buy at StockNews.com - Defense World

Aug 12, 2024

Finanzdaten der Lipocine Inc-Aktie (LPCN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):